Re: Q3 earnings call Friday November 1
I believe that language is normal for their releases. I would hope that by then they can discuss presentations of their and partners products at the technical conferences coming up by the end of the year.
Right now I believe that one or more partnerships could be the thing that moves the stock the most. I still believe that IMGN853 in a ROW partnership should bring in substantial funds, but clearly not what it would have brought if we were still expecting an approval next year. At this point little is unknown about what's needed to gain approval, the major unknown is what it will do in other cancers with high platinum resistant patients. A BP partner might be willing to fund additional trials in other cancers, but if not, it will almost certainly happen post approval for ovarian cancer.